Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease

Leukemia Research

Volumn 35, Issue 10, 2011, Pages 1290-1293

  D'Alessio, F ^a,b   Mirabelli, P ^a,b   Mariotti, E ^a,b   Raia, M ^a,b   di Noto, R ^a,b   Fortunato, G ^a,b   Camera, A ^a,b   del Vecchio, L ^a,b  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

BCR ABL oncoprotein; Cerebrospinal fluid; Flow cytometry; Immunobead assay; Philadelphia positive leukemia

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CASE REPORT; CELL ISOLATION; CEREBROSPINAL FLUID ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; EVIDENCE BASED MEDICINE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOPHENOTYPING; LEPTOMENINGEAL DISEASE; LEUKEMIA CELL; LIMIT OF DETECTION; MENINX DISORDER; MOLECULAR DIAGNOSIS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

DIAGNOSIS, DIFFERENTIAL; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOASSAY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MENINGEAL NEOPLASMS; PHILADELPHIA CHROMOSOME; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SENSITIVITY AND SPECIFICITY;

EID: 80052086278     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.016     Document Type: Article

References (14)

1. Pfeifer H., Wassmann B., Hofmann W.K., Komor M., Scheuring U., Brück P., et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003, 9:4674-4681.
2. Porkka K., Koskenvesa P., Lundán T., Rimpiläinen J., Mustjoki S., Smykla R., et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008, 112:1005-1012.
3. Weerkamp F., Dekking E., Ng Y.Y., van der Velden V.H.J., Wai H., Bottcher S., et al. Flow cytometry immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia 2009, 23:1106-1117.
4. Pui C.H., Thiel E. Central nervous system disease in hematological malignancies: historical perspective and practical applications. Semin Oncol 2009, 36:S2-S16.
5. Di Noto R., Scalia G., Abate G., Gorrese M., Pascariello C., Raia M., et al. Critical role of multidimensional flow cytometry in detecting occult leptomeningeal disease in newly diagnosed aggressive B-cell lymphomas. Leuk Res 2008, 32:1196-1199.
6. Subirá D., Castañón S., Román A., Aceituno E., Jiménez-Garófano C., Jiménez A., et al. Flow cytometry and the study of central nervous disease in patients with acute leukemia. Brit J Haematol 2001, 112:381-384.
7. Haskovec C., Ponzetto C., Polak J., Maritano D., Zemanova Z., Serra A., et al. P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. Brit J Haematol 1998, 103:1104-1108.
8. Raponi S., De Propris M.S., Wai H., Intoppa S., Elia L., Diverio D., et al. An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia. Haematologica 2009, 94:1767-1770.
9. Isobe Y., Sugimoto K., Masuda A., Hamano Y., Oshimi K. Central nervous system is a sanctuary site for chronic myeloid leukaemia treated with imatinib mesylate. Intern Med J 2009, 39:408-411.
10. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
11. Blimkie D., Fortuno E.S., Thommai F., Xu L., Fernandes E., Crabtree J., et al. Identification of B cells through negative gating-an example of MIFlowCyt standard applied. Cytometry A 2010, 77:546-551.
12. Huh H.J., Huh J.W., Seong C.M., Lee M., Chung W.S. Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the philadelphia chromosome. Am J Hematol 2003, 74:218-220.
13. Alsop S., Sanger W.G., Elenitoba-Johnson K.S.J., Lim M.S. Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma. Hum Pathol 2007, 38:1576-1580.
14. Specchia G., Buquicchio C., Albano F., Liso A., Pannunzio A., Mestice A., et al. Non-treatment-related chronic myeloid leukemia as a second malignancy. Leuk Res 2004, 28:115-119.